RT-PCR Protocols
DOI: 10.1385/1-59259-283-x:093
|View full text |Cite
|
Sign up to set email alerts
|

Rapid Development of a Quantitative-Competitive (qc) RT-PCR Assay Using a Composite Primer Approach

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
5
0

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(5 citation statements)
references
References 2 publications
0
5
0
Order By: Relevance
“…On one hand the competitor product has to be distinguishable from the native template but at the same time too much of difference in their size may cause differences in amplification efficiency. As a solution to handle with this problem it is generally recommended that the size difference between the target and competitor product should not be more than 30% (O'Connell et al. 2002).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…On one hand the competitor product has to be distinguishable from the native template but at the same time too much of difference in their size may cause differences in amplification efficiency. As a solution to handle with this problem it is generally recommended that the size difference between the target and competitor product should not be more than 30% (O'Connell et al. 2002).…”
Section: Discussionmentioning
confidence: 99%
“…2000). However, in competitive PCR because two templates (target and competitor) compete for PCR amplification it may be necessary to perform PCR for more number of cycles to achieve good amplification of both templates specially when the target copy number is very low and at the lower limit of detection (O'Connell et al. 2002).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The plasmid thus obtained (pBS/competitor A + B) contained competitors for AML1a and AML1b in back-to-back orientation, with 1,250 bp of intervening spacer. This pBS/competitor A + B was used for the competitive PCR for both AML1a and AML1b/AML1 c to quantitate AML1 isoforms in a given cell population [34]. Total RNA was isolated from the fractionated cord blood cells using Trizol reagent (Invitrogen, http://www.invitrogen.com) and then reverse-transcribed using random primers and Superscript II enzyme according to the manufacturers' instructions.…”
Section: Methodsmentioning
confidence: 99%
“…PCR products were then fractionated on a 2.5% agarose gel electrophoresis, and the PCR products from endogenous AML1 and from the competitor plasmid were quantitated densitometrically. The amounts of the endogenous AML1 isoforms were then estimated as described [34] and normalized on the basis of G6PD expression estimated by a quantitative real-time PCR [35]. …”
Section: Methodsmentioning
confidence: 99%